{{Rsnum
|rsid=2607347
|Gene=PDE4D
|Chromosome=5
|position=59425783
|Orientation=minus
|GMAF=0.3246
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=PDE4D
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 32.7 | 45.1 | 22.1
| HCB | 58.6 | 36.1 | 5.3
| JPT | 57.1 | 33.9 | 8.9
| YRI | 73.8 | 23.4 | 2.8
| ASW | 49.1 | 45.6 | 5.3
| CHB | 58.6 | 36.1 | 5.3
| CHD | 63.6 | 28.0 | 8.4
| GIH | 64.0 | 32.0 | 4.0
| LWK | 65.4 | 29.0 | 5.6
| MEX | 33.3 | 45.6 | 21.1
| MKK | 42.6 | 46.5 | 11.0
| TSI | 31.4 | 48.0 | 20.6
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2607347
|Name_s=
|Gene_s=PDE4D
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00006. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109446
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2607347
|overall_frequency_n=41
|overall_frequency_d=128
|overall_frequency=0.320312
|n_genomes=30
|n_genomes_annotated=0
|n_haplomes=35
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}